Cybin Inc. Common Stock (HELP) - Total Assets
Based on the latest financial reports, Cybin Inc. Common Stock (HELP) holds total assets worth $398.07 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See HELP total equity for net asset value and shareholders' equity analysis.
Cybin Inc. Common Stock - Total Assets Trend (2017–2025)
This chart illustrates how Cybin Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Cybin Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (March 2025)
Cybin Inc. Common Stock's total assets of $398.07 Million consist of 64.2% current assets and 35.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 52.2% |
| Accounts Receivable | $5.88 Million | 2.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $41.02 Million | 15.9% |
| Goodwill | $51.49 Million | 19.9% |
Asset Composition Trend (2017–2025)
This chart illustrates how Cybin Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Cybin Inc. Common Stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cybin Inc. Common Stock's current assets represent 64.2% of total assets in 2025, a decrease from 97.7% in 2017.
- Cash Position: Cash and equivalents constituted 52.2% of total assets in 2025, down from 97.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 19.9% of total assets.
Cybin Inc. Common Stock Competitors by Total Assets
Key competitors of Cybin Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Cybin Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.78 | 12.60 | 13.57 |
| Quick Ratio | 13.78 | 12.60 | 13.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $283.64 Million | $154.38 Million | $61.58 Million |
Cybin Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Cybin Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | -14.4% |
| Total Assets | $258.62 Million |
| Market Capitalization | $233.50 Million USD |
Valuation Analysis
Near Book Valuation: The market values Cybin Inc. Common Stock's assets close to their book value (0.90x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Cybin Inc. Common Stock's assets decreased by 14.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cybin Inc. Common Stock (2017–2025)
The table below shows the annual total assets of Cybin Inc. Common Stock from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $258.62 Million | -14.37% |
| 2024-03-31 | $302.02 Million | +460.37% |
| 2023-03-31 | $53.90 Million | -35.88% |
| 2022-03-31 | $84.06 Million | -8.74% |
| 2021-03-31 | $92.11 Million | +5283.52% |
| 2020-03-31 | $1.71 Million | +318.97% |
| 2019-03-31 | $408.38K | -10.48% |
| 2018-03-31 | $456.18K | +2.96% |
| 2017-03-31 | $443.08K | -- |
About Cybin Inc. Common Stock
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical tr… Read more